Solid Tumor Cancer Treatment Market (By Type: Sarcomas, Carcinomas; By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy; By Route of Administration: Oral, Parenteral, Others; By End-Users: Hospitals, Research Institutes, Homecare) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global solid tumor cancer treatment market size was exhibited at USD 186.9 billion in 2022 and is projected to hit around USD 535.01 billion by 2032, growing at a CAGR of 11.09% during the forecast period 2023 to 2032.

Key Pointers:

• North America currently dominates the market for solid tumor therapeutics, and it is expected to continue its stronghold for a few more years
• By Type, the Sarcomas is expected to record the maximum market share between 2023 and 2032.
• By Treatment, the Chemotherapy segment is expected to expand at a remarkable CAGR between 2023 and 2032.
• By Route of Administration, the Oral segment is projected to dominate the market between 2023 and 2032.
• By End User, the Hospitals segment is predicted to capture a notable market share between 2023 and 2032.

Solid Tumor Cancer Treatment Market Report Scope

The major factors that are responsible for the growth of this market include new product approvals in ovarian, pancreatic, and prostate cancers, and increasing government initiatives for cancer awareness. In addition, the other crucial driving factor is the increasing incidence of cancer. For instance, cancer has a significant impact on societies across the world. The most common cancers in 2016 were breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, leukemia, endometrial cancer, and pancreatic cancer.

Cancer rates could further increase by 50%, to 16 million new cases by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could prevent this trend and prevent as many as one-third of all cancers, worldwide. The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,211 estimated new cancer cases and 595,690 deaths, due to cancer in 2016, in the United States. Hence, the increasing number of patients is expected to drive the market during the forecast period. However, factors, such as stringent regulatory reforms and price erosion due to generic competition may hinder the growth of this market.

North America currently dominates the market for solid tumor therapeutics, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to increasing incidence rates of cancer and increasing awareness among people, and the presence of developed healthcare infrastructure are propelling the growth of the market in the forecast period.

Some of the prominent players in the Solid Tumor Cancer Treatment Market include:

• F.Hoffman- La Roche Ltd.
• Mylan N.V.
• Sanofi
• Pfizer
• Merck & Co
• Allergan 
• AstraZeneca
• Novartis AG
•  Bayer AG
• Lupin

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Solid Tumor Cancer Treatment market.

By Type

• Sarcomas
• Carcinomas

By Treatment

• Chemotherapy
• Immunotherapy
• Targeted Therapy

By Route of Administration

• Oral
• Parenteral
• Others

By End-Users

• Hospitals
• Research Institutes
• Homecare

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)